Mrs. Feryal Dabbagh-Gorjani – Tumor Immunology – Best Researcher Award

Mrs. Feryal Dabbagh-Gorjani - Tumor Immunology - Best Researcher Award

Foroogh Salamat - Iran

Author Profile

Orcid

EARLY ACADEMIC PURSUITS

Feryal Dabbagh Gorjani embarked on her academic journey with a strong foundation in the medical sciences. She pursued a B.Sc in Clinical Laboratory from 2008 to 2010 at the Preclinical School of Iran University of Medical Science, Tehran, Iran. Prior to that, she obtained an associated degree in Clinical Laboratory from the Preclinical School of Islamic Azad University, Tehran Medical Sciences Branch, from 2005 to 2007. Her educational journey culminated in an M.Sc in Medical Immunology from 2011 to 2014 at the Medical School of Shiraz University of Medical Science, Shiraz, Iran.

PROFESSIONAL ENDEAVORS

From December 2023 onwards, Feryal Dabbagh Gorjani has been engaged as a medical advisor at Forough Salamat Mehregan, the official representative of the American company Fairhaven Health. Her role in this capacity involves providing expertise and guidance in medical matters, presumably within the realm of immunology and clinical laboratory science.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY

Throughout her academic and professional journey, Feryal Dabbagh Gorjani has likely contributed to the field of medical immunology and clinical laboratory science. And her Specific research focuses on immunological diagnostics, disease pathogenesis, and therapeutic interventions.

IMPACT AND INFLUENCE

Her work as a medical advisor suggests that she plays a crucial role in shaping decisions related to health and wellness. Her expertise in medical immunology and clinical laboratory science likely contributes to advancements in diagnostic accuracy, treatment efficacy, and patient care.

LEGACY AND FUTURE CONTRIBUTIONS HIGHLIGHT

Feryal Dabbagh Gorjani's legacy and future contributions lie in her ongoing work as a medical advisor and her potential for further advancements in the fields of medical immunology and clinical laboratory science. As she continues to apply her expertise and knowledge in healthcare settings, her contributions are likely to impact patient outcomes, research advancements, and the broader medical community. Future endeavors may include continued research, publications, and collaborative efforts to address emerging challenges in immunological diagnostics and therapeutics.

Notable Publications

A Comprehensive Review on the Role of Interleukin-40 as a Biomarker for Diagnosing Inflammatory Diseases. 2024

COVID-19 and neurological complications. 2022

EcoImmunology: Evaluative Aspects and Future Perspectives. 2018

Investigating the Association of IL-17A and IL-17F with Susceptibility to Preeclampsia in Iranian Women. 2015

Differences in the expression of TLRs and inflammatory cytokines in preeclamptic compared with healthy pregnant women. 2014

 

 

 

 

Biomedical Advancements in Cancer

Biomedical Advancements in Cancer

 

Introduction: In recent years, the field of biomedical advancements in cancer research has witnessed remarkable breakthroughs that have transformed our understanding of the disease and revolutionized treatment options. These advancements offer new hope to patients and hold the promise of improved outcomes in the fight against cancer.

Subtopics in Biomedical Advancements in Cancer:

Immunotherapy and Immune Checkpoint Inhibitors: Immune checkpoint inhibitors have emerged as a game-changer in cancer treatment, leveraging the body’s immune system to target and eliminate cancer cells. CAR-T cell therapy, PD-1 inhibitors, and CTLA-4 inhibitors are some of the key developments in this area.

Precision Medicine and Genomic Profiling: Advancements in genomic sequencing technologies have paved the way for precision medicine in cancer treatment. Tailoring therapies based on the genetic makeup of a patient’s tumor has improved treatment efficacy and reduced side effects.

Liquid Biopsies for Early Detection: Liquid biopsies involve the non-invasive analysis of blood or other bodily fluids to detect cancer-related genetic mutations and biomarkers. These tests offer early detection capabilities and real-time monitoring of cancer progression.

Targeted Therapies and Personalized Cancer Drugs: Targeted therapies are designed to specifically inhibit the molecular pathways driving cancer growth. Advances in drug development have led to a wide range of targeted treatments, enhancing the effectiveness of cancer therapy while minimizing collateral damage to healthy cells.

AI and Machine Learning in Cancer Diagnosis and Treatment: Artificial intelligence and machine learning algorithms are being employed to analyze vast datasets of medical information, aiding in early cancer diagnosis, treatment planning, and predicting patient outcomes. These technologies have the potential to optimize cancer care and streamline research efforts.

These subtopics represent just a fraction of the exciting developments in the biomedical field related to cancer research. Continued research and innovation in these areas are bringing us closer to more effective treatments, early detection methods, and improved patient outcomes in the battle against cancer.